Negative control for the Src kinase inhibitor PP2.
Biological descriptionNegative control for the Src kinase inhibitor PP2 (ab120308). Inhibits EGFR kinase (IC50 = 2.7 μM).
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 100 mM and in ethanol to 25 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
ab11512 staining E cadherin in SW480 cells treated with PP3 (ab120617), by ICC/IF. No change of E cadherin expression with increased concentration of PP3 is observed, as described in literature, since PP3 is the negative control for PP2. The cells were incubated at 37°C for 24h in media containing different concentrations of ab120617 (PP3) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab11512 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rat polyclonal antibody (ab98386) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
References for PP3 (ab120617)
This product has been referenced in:
Hou XY et al. PP2, a potent inhibitor of Src family kinases, protects against hippocampal CA1 pyramidal cell death after transient global brain ischemia. Neurosci Lett420:235-9 (2007).
Read more (PubMed: 17556100) »
Traxler P et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem40:3601-16 (1997).
Read more (PubMed: 9357527) »